Ginkgo Bioworks Holdings, Inc. — Form 8-K Summary
Business context and reporting period
Ginkgo filed this Current Report on January 27, 2023, to provide updated financial information related to its acquisition of Zymergen Inc., which was completed on October 19, 2022. The filing includes Zymergen’s unaudited interim financial statements for the quarterly period ended September 30, 2022, together with unaudited pro forma combined financial information reflecting the acquisition.
Financial information provided
- Zymergen’s unaudited consolidated interim financial statements are included as Exhibit 99.1.
- Unaudited pro forma condensed combined financial information includes a balance sheet as of September 30, 2022.
- Unaudited pro forma condensed combined statements of operations cover the nine months ended September 30, 2022, and the year ended December 31, 2021.
- The filing text provided does not include clear values for revenue, profit or loss, cash flow, margins, debt, liquidity, or other financial metrics; those details are contained in the referenced exhibits.
Material changes versus prior comparable period
The principal reported change is the inclusion of updated Zymergen financial statements and updated pro forma information following Ginkgo’s acquisition of Zymergen. The filing text does not provide enough numerical detail to assess period-over-period changes in operating or financial performance.
Guidance, outlook, risks, contingencies, and unusual items
The filing does not provide new guidance, an outlook, management commentary, risk-factor updates, contingencies, or unusual-item discussion. The principal transaction-related item is the completed acquisition of Zymergen and its presentation in pro forma financial statements.
Investor verification items
- Review Exhibit 99.1 for Zymergen’s revenue, operating results, cash position, liabilities, and other interim financial information.
- Review Exhibit 99.2 for acquisition adjustments, pro forma combined results, and the effect of the transaction on Ginkgo’s reported financial position and operations.
- Confirm the assumptions and transaction accounting reflected in the unaudited pro forma presentation.
- Assess any liquidity, integration, impairment, restructuring, or other risks disclosed in the attached financial statements and notes.